Home Stock

Stock Research: Esperion Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Esperion Therapeutics

NMQ:ESPR US29664W1053
97
  • Value
    100
  • Growth
    90
  • Safety
    Safety
    85
  • Combined
    100
  • Sentiment
    3
  • 360° View
    360° View
    97
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for cardiovascular disease. Its products include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, aimed at lowering elevated LDL-C and cardiovascular risk. In the last fiscal year, the company had 304 employees, a market cap of $228 million, profits of $264 million, and revenue of $332 million.

more

ANALYSIS: With an Obermatt 360° View of 97 (better than 97% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Esperion Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Esperion Therapeutics. The consolidated Value Rank has an attractive rank of 100, which means that the share price of Esperion Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 100% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 90, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 85. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 3. Professional investors are more confident in 97% other stocks. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Value
Country USA
Industry Pharmaceuticals
Size Small
Website esperion.com
Index
NASDAQ
Esperion Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 80 88 55
Growth
90 77 33 7
Safety
Safety
85 37 28 8
Sentiment
3 10 45 1
360° View
360° View
97 47 39 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 36 57 9
Opinions Change
4 31 50 37
Pro Holdings
n/a 28 32 53
Market Pulse
5 11 48 20
Sentiment
3 10 45 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 80 88 55
Growth
90 77 33 7
Safety Safety
85 37 28 8
Combined
100 84 49 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
100 76 82 38
Price vs. Earnings (P/E)
100 7 100 14
Price vs. Book (P/B)
72 92 100 92
Dividend Yield
1 1 1 1
Value
100 80 88 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
45 43 98 17
Profit Growth
94 86 51 12
Capital Growth
43 98 1 95
Stock Returns
84 29 11 5
Growth
90 77 33 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
5 25 14 1
Refinancing
96 74 73 69
Liquidity
100 24 31 23
Safety Safety
85 37 28 8

Similar Stocks

Discover high‑ranked alternatives to Esperion Therapeutics and broaden your portfolio horizons.

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews